Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFG |
dARK ID: | ark:/38995/001300000b9wz |
Texto Completo: | http://repositorio.bc.ufg.br/tede/handle/tede/8601 |
Resumo: | Skin cancer has the highest incidence among all types of neoplasms and the tendency is the increasing number of new cases in next decades, wich makes necessary new modalities and treatment options. Chemotherapeutic agent imiquimod is used in treatment of disease, but the high occurrence of local and systemic adverse effects associated with its use as well as its low skin permeation impair adherence and therapeutical effectiveness, respectively. The aim of the present work was evaluate the antitumor activity of nanocapsules imiquimod-loaded compared to its commercial product in murine model of skin cancer. Polymeric nanocapsules containing imiquimod, in the absence and presence of chitosan coating, were obtained by the precipitation of preformed polymer technique and characterized by encapsulation efficiency, size, zeta potential, pH, morphology (transmission electron microscopy and scanning), optical scanning spectrophotometry and in vitro release through dialysis membrane in pH 5.6 buffer. Presence of chemical interactions between formulation components was evaluated by thermogravimetric analysis and infrared spectroscopy. Detection of crystalline structures was performed by X-ray diffractometry. The nanocapsules and commercial imiquimod formulation antiagiogenic activity was determined in a chicken embryo chorioallantoic membrane model. Cutaneous permeation of nanocapsules imiquimod-loaded and commercial imiquimod was determined in Swiss albino mice. The chemopreventive activity of colloidal dispersions and the commercial imiquimod was evaluated through the tumoral inhibition promoted by these treatments in a multi- stage model of chemical carcinogenesis in Swiss mice. Encapsulation efficiency, mean diameter, zeta potential and pH of uncoated nanocapsules imiquimod-loaded were 92.5% ± 0.4; 249 ± 22.4 nm; -40.1 mV ± 3.7 and 5.4 ± 0.01 respectively, whereas for nanocapsules with cationic coating the parameters found were: 88.6 ± 2.3%; 287.0 ± 12.6 nm; + 11.3 ± 0.5 mV and 3.7 ± 0.0, respectively. The formulations morphology obtained by scanning and transmission electron microscopy images confirmed the presence of nanocapsules. In the stability analysis by optical scanning spectrophotometry (Turbiscan), all dispersions obtained a backscattering variation less than 2% over 5 weeks and were considered stable. In the in vitro release assay, imiquimod-loaded nanoparticles obtained slower release of the drug compared to free and commercial imiquimod. There were chemical interactions between chitosan and other formulation components evaluated by thermogravimetric and infrared studies. No crystalline structure was detected by the X-ray diffraction technique for the coated and uncoated imiquimod formulation. The dispersion of nanocapsules containing imiquimod presented antiangiogenic activity superior than commercial formulation in chicken embryo chorioallantoic membrane model. Nanocapsules containing imiquimod both uncoated and coated with chitosan presented cutaneous permeation in deep layers of the skin and inhibition in the chemically induced carcinogenicity process superior than tumor control group and groups treated with placebo nanoparticles while the commercial formulation presented retention of the drug in superficial layers of the skin and did not obtain a statistically significant reduction in the number of papillomas formed compared to the carcinogenic control. These results allow to conclude, therefore, that stable nanocarreadores were obtained and the chemopreventive activity and the antiangiogenic effect of these systems represent a promising alternative for the treatment of cutaneous neoplasias. |
id |
UFG-2_fc3e2688fb2d43aa6da05b983869d334 |
---|---|
oai_identifier_str |
oai:repositorio.bc.ufg.br:tede/8601 |
network_acronym_str |
UFG-2 |
network_name_str |
Repositório Institucional da UFG |
repository_id_str |
|
spelling |
Silva Júnior, Armando da Cunhahttp://lattes.cnpq.br/8278273904187275Lima, Eliana MartinsSerakides, RogériaBarros, André Luís Branco dePereira, Bruno Gonçalveshttp://lattes.cnpq.br/1789462070390929Dias, Marina França2018-06-27T11:09:43Z2018-04-11DIAS, Marina França. Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele. 2018. 102 f. Tese (Doutorado em Nanotecnologia Farmacêutica em Rede) - Universidade Federal de Goiás, Goiânia, 2018.http://repositorio.bc.ufg.br/tede/handle/tede/8601ark:/38995/001300000b9wzSkin cancer has the highest incidence among all types of neoplasms and the tendency is the increasing number of new cases in next decades, wich makes necessary new modalities and treatment options. Chemotherapeutic agent imiquimod is used in treatment of disease, but the high occurrence of local and systemic adverse effects associated with its use as well as its low skin permeation impair adherence and therapeutical effectiveness, respectively. The aim of the present work was evaluate the antitumor activity of nanocapsules imiquimod-loaded compared to its commercial product in murine model of skin cancer. Polymeric nanocapsules containing imiquimod, in the absence and presence of chitosan coating, were obtained by the precipitation of preformed polymer technique and characterized by encapsulation efficiency, size, zeta potential, pH, morphology (transmission electron microscopy and scanning), optical scanning spectrophotometry and in vitro release through dialysis membrane in pH 5.6 buffer. Presence of chemical interactions between formulation components was evaluated by thermogravimetric analysis and infrared spectroscopy. Detection of crystalline structures was performed by X-ray diffractometry. The nanocapsules and commercial imiquimod formulation antiagiogenic activity was determined in a chicken embryo chorioallantoic membrane model. Cutaneous permeation of nanocapsules imiquimod-loaded and commercial imiquimod was determined in Swiss albino mice. The chemopreventive activity of colloidal dispersions and the commercial imiquimod was evaluated through the tumoral inhibition promoted by these treatments in a multi- stage model of chemical carcinogenesis in Swiss mice. Encapsulation efficiency, mean diameter, zeta potential and pH of uncoated nanocapsules imiquimod-loaded were 92.5% ± 0.4; 249 ± 22.4 nm; -40.1 mV ± 3.7 and 5.4 ± 0.01 respectively, whereas for nanocapsules with cationic coating the parameters found were: 88.6 ± 2.3%; 287.0 ± 12.6 nm; + 11.3 ± 0.5 mV and 3.7 ± 0.0, respectively. The formulations morphology obtained by scanning and transmission electron microscopy images confirmed the presence of nanocapsules. In the stability analysis by optical scanning spectrophotometry (Turbiscan), all dispersions obtained a backscattering variation less than 2% over 5 weeks and were considered stable. In the in vitro release assay, imiquimod-loaded nanoparticles obtained slower release of the drug compared to free and commercial imiquimod. There were chemical interactions between chitosan and other formulation components evaluated by thermogravimetric and infrared studies. No crystalline structure was detected by the X-ray diffraction technique for the coated and uncoated imiquimod formulation. The dispersion of nanocapsules containing imiquimod presented antiangiogenic activity superior than commercial formulation in chicken embryo chorioallantoic membrane model. Nanocapsules containing imiquimod both uncoated and coated with chitosan presented cutaneous permeation in deep layers of the skin and inhibition in the chemically induced carcinogenicity process superior than tumor control group and groups treated with placebo nanoparticles while the commercial formulation presented retention of the drug in superficial layers of the skin and did not obtain a statistically significant reduction in the number of papillomas formed compared to the carcinogenic control. These results allow to conclude, therefore, that stable nanocarreadores were obtained and the chemopreventive activity and the antiangiogenic effect of these systems represent a promising alternative for the treatment of cutaneous neoplasias.O câncer de pele é o de maior incidência dentre todos os tipos de neoplasias e a tendência é o aumento crescente do número de novos casos nas próximas décadas, tornando necessárias novas modalidades e opções de tratamento. O agente quimio-terápico imiquimode é utilizado no tratamento da doença, mas a elevada ocorrência de efeitos adversos locais e sistêmicos associados ao seu uso bem como sua baixa permeação cutânea prejudicam a adesão e a efetividade terapêutica, respectiva-mente. O objetivo do presente trabalho foi comparar a atividade quimiopreventiva do imiquimode veiculado em nanocápsulas com a da sua forma comercial, em modelo murino de câncer de pele. Nanocápsulas poliméricas contendo o imiquimode, na ausência e presença de revestimento de quitosana, foram obtidas pela técnica de precipitação do polímero pré-formado e caracterizadas quanto à eficiência de encap-sulação, ao tamanho, ao potencial zeta, ao pH, à morfologia (microscopia eletrônica de transição e varredura), à espectrofotometria de varredura óptica e à liberação in vitro através de membrana de diálise em tampão pH 5,6. A presença de interações entre componentes da formulação foi avaliada por meio de análises termogravimé- tricas e por espectroscopia na região do infravermelho. A detecção de estruturas cristalinas nas formulações foi realizada por difratometria de raios X. A atividade antiangiogênica das nanocápsulas obtidas, bem como da formulação comercial do imiquimode, foi determinada em modelo de membrana corioalantoica de embrião de galinha. A permeação cutânea das nanopartículas e do imiquimode comercial foi determinada em camundongos Swiss. A atividade quimiopreventiva das nanocápsulas obtidas e a do imiquimode comercial foi avaliada por meio da inibição tumoral promovida por esses tratamentos em modelo de carcinogênese química em camundongos Swiss. A eficiência de encapsulação, o diâmetro médio, o potencial zeta e o pH das nanocápsulas não revestidas contendo imiquimode foram respectivamente de 92,5% ± 0,4; 249 ± 22,4 nm; -40,1 mV ± 3,7 e 5,4 ± 0,01. Enquanto que, para as nanocápsulas com recobrimento catiônico os parâmetros encontrados foram 88,6 ± 2,3%; 287,0 ± 12,6 nm; +11,3 ± 0,5 mV e 3,7 ± 0,0, respectivamente. A morfologia das formulações, obtida pelas imagens de microscopia eletrônica de varredura e de transmissão, confirmou a presença de nanocápsulas. Nas análises de estabilidade por espectrofotometria de varredura óptica (Turbiscan), todas as dispersões obtiveram variação de retroespalhamento inferior a 2%, no período de cinco semanas, sendo consideradas estáveis. No ensaio de liberação in vitro, as nanopartículas contendo imiquimode obtiveram liberação mais lenta do fármaco comparativamente ao imiquimode livre (em solução) e ao imiquimode comercial. Foram verificadas interações entre a quitosana e os demais componentes das formulações nos estudos termogravimétricos e na espectroscopia na região do infravermelho. Não foi detectada presença de estrutura cristalina com emprego da técnica de difratometria de raios X para a formulações contendo imiquimode com e sem revestimento. A dispersão de nanocápsulas contendo imiquimode apresentou atividade antiangiogênica superior à da formulação comercial em modelo de membrana corioalantoica de embrião de galinha. As nanocápsulas contendo imi-quimode com e sem revestimento apresentaram permeação cutânea em camadas profundas da pele e inibição no processo de carcinogênese quimicamente induzido superior à do grupo-controle tumoral e à dos grupos tratados com nanopartículas placebo, enquanto a formulação comercial apresentou retenção do fármaco em camadas mais superficiais da pele e não obteve redução estatisticamente significativa no número de papilomas formados em relação ao controle cancerígeno. Esses resultados permitem concluir, portanto, que nanocarreadores estáveis foram obtidos e que a atividade quimiopreventiva e o efeito antiangiogênico desses sistemas representam uma alternativa promissora para o tratamento de neoplasias cutâneas.Submitted by Franciele Moreira (francielemoreyra@gmail.com) on 2018-06-22T19:23:21Z No. of bitstreams: 2 Tese - Marina França Dias - 2018.pdf: 4770115 bytes, checksum: 86e73a57e2ce0a02cb1666dfe5988ce3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-06-27T11:09:43Z (GMT) No. of bitstreams: 2 Tese - Marina França Dias - 2018.pdf: 4770115 bytes, checksum: 86e73a57e2ce0a02cb1666dfe5988ce3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2018-06-27T11:09:43Z (GMT). No. of bitstreams: 2 Tese - Marina França Dias - 2018.pdf: 4770115 bytes, checksum: 86e73a57e2ce0a02cb1666dfe5988ce3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2018-04-11Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPqapplication/pdfporUniversidade Federal de GoiásPrograma de Pós-graduação em Nanotecnologia Farmacêutica em Rede (FF)UFGBrasilFaculdade Farmácia - FF (RG)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessCâncer de peleNanopartículasImiquimodeAtividade antiangiogênicaQuimioprevençãoSkin câncerNanoparticlesImiquimodAntiangiogenic activityChemopreventionFARMACIA::FARMACOTECNIADesenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de peleDevelopment and evaluation of the chemopreventive activity of nanoparticles containing imiquimod in murine model of skin cancerinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesis-89454519598569253156006006006006010281161524209375-1498234366838932019-2555911436985713659reponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGLICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://repositorio.bc.ufg.br/tede/bitstreams/a7689134-9d4d-48ec-a690-408a8f609778/downloadbd3efa91386c1718a7f26a329fdcb468MD51CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://repositorio.bc.ufg.br/tede/bitstreams/58ab8ea3-50bc-4bf5-b127-ccc4bf82af06/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/5f262478-1342-4498-a54f-5758b5ff9bf7/downloadd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/934ac161-3de4-4371-99d2-7f8933672dd0/downloadd41d8cd98f00b204e9800998ecf8427eMD54ORIGINALTese - Marina França Dias - 2018.pdfTese - Marina França Dias - 2018.pdfapplication/pdf4770115http://repositorio.bc.ufg.br/tede/bitstreams/9b73a680-d874-412b-b3d2-5d1615870762/download86e73a57e2ce0a02cb1666dfe5988ce3MD55tede/86012023-04-28 08:07:34.165http://creativecommons.org/licenses/by-nc-nd/4.0/Acesso Abertoopen.accessoai:repositorio.bc.ufg.br:tede/8601http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2023-04-28T11:07:34Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)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 |
dc.title.eng.fl_str_mv |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
dc.title.alternative.eng.fl_str_mv |
Development and evaluation of the chemopreventive activity of nanoparticles containing imiquimod in murine model of skin cancer |
title |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
spellingShingle |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele Dias, Marina França Câncer de pele Nanopartículas Imiquimode Atividade antiangiogênica Quimioprevenção Skin câncer Nanoparticles Imiquimod Antiangiogenic activity Chemoprevention FARMACIA::FARMACOTECNIA |
title_short |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
title_full |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
title_fullStr |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
title_full_unstemmed |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
title_sort |
Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele |
author |
Dias, Marina França |
author_facet |
Dias, Marina França |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Silva Júnior, Armando da Cunha |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/8278273904187275 |
dc.contributor.referee1.fl_str_mv |
Lima, Eliana Martins |
dc.contributor.referee2.fl_str_mv |
Serakides, Rogéria |
dc.contributor.referee3.fl_str_mv |
Barros, André Luís Branco de |
dc.contributor.referee4.fl_str_mv |
Pereira, Bruno Gonçalves |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/1789462070390929 |
dc.contributor.author.fl_str_mv |
Dias, Marina França |
contributor_str_mv |
Silva Júnior, Armando da Cunha Lima, Eliana Martins Serakides, Rogéria Barros, André Luís Branco de Pereira, Bruno Gonçalves |
dc.subject.por.fl_str_mv |
Câncer de pele Nanopartículas Imiquimode Atividade antiangiogênica Quimioprevenção |
topic |
Câncer de pele Nanopartículas Imiquimode Atividade antiangiogênica Quimioprevenção Skin câncer Nanoparticles Imiquimod Antiangiogenic activity Chemoprevention FARMACIA::FARMACOTECNIA |
dc.subject.eng.fl_str_mv |
Skin câncer Nanoparticles Imiquimod Antiangiogenic activity Chemoprevention |
dc.subject.cnpq.fl_str_mv |
FARMACIA::FARMACOTECNIA |
description |
Skin cancer has the highest incidence among all types of neoplasms and the tendency is the increasing number of new cases in next decades, wich makes necessary new modalities and treatment options. Chemotherapeutic agent imiquimod is used in treatment of disease, but the high occurrence of local and systemic adverse effects associated with its use as well as its low skin permeation impair adherence and therapeutical effectiveness, respectively. The aim of the present work was evaluate the antitumor activity of nanocapsules imiquimod-loaded compared to its commercial product in murine model of skin cancer. Polymeric nanocapsules containing imiquimod, in the absence and presence of chitosan coating, were obtained by the precipitation of preformed polymer technique and characterized by encapsulation efficiency, size, zeta potential, pH, morphology (transmission electron microscopy and scanning), optical scanning spectrophotometry and in vitro release through dialysis membrane in pH 5.6 buffer. Presence of chemical interactions between formulation components was evaluated by thermogravimetric analysis and infrared spectroscopy. Detection of crystalline structures was performed by X-ray diffractometry. The nanocapsules and commercial imiquimod formulation antiagiogenic activity was determined in a chicken embryo chorioallantoic membrane model. Cutaneous permeation of nanocapsules imiquimod-loaded and commercial imiquimod was determined in Swiss albino mice. The chemopreventive activity of colloidal dispersions and the commercial imiquimod was evaluated through the tumoral inhibition promoted by these treatments in a multi- stage model of chemical carcinogenesis in Swiss mice. Encapsulation efficiency, mean diameter, zeta potential and pH of uncoated nanocapsules imiquimod-loaded were 92.5% ± 0.4; 249 ± 22.4 nm; -40.1 mV ± 3.7 and 5.4 ± 0.01 respectively, whereas for nanocapsules with cationic coating the parameters found were: 88.6 ± 2.3%; 287.0 ± 12.6 nm; + 11.3 ± 0.5 mV and 3.7 ± 0.0, respectively. The formulations morphology obtained by scanning and transmission electron microscopy images confirmed the presence of nanocapsules. In the stability analysis by optical scanning spectrophotometry (Turbiscan), all dispersions obtained a backscattering variation less than 2% over 5 weeks and were considered stable. In the in vitro release assay, imiquimod-loaded nanoparticles obtained slower release of the drug compared to free and commercial imiquimod. There were chemical interactions between chitosan and other formulation components evaluated by thermogravimetric and infrared studies. No crystalline structure was detected by the X-ray diffraction technique for the coated and uncoated imiquimod formulation. The dispersion of nanocapsules containing imiquimod presented antiangiogenic activity superior than commercial formulation in chicken embryo chorioallantoic membrane model. Nanocapsules containing imiquimod both uncoated and coated with chitosan presented cutaneous permeation in deep layers of the skin and inhibition in the chemically induced carcinogenicity process superior than tumor control group and groups treated with placebo nanoparticles while the commercial formulation presented retention of the drug in superficial layers of the skin and did not obtain a statistically significant reduction in the number of papillomas formed compared to the carcinogenic control. These results allow to conclude, therefore, that stable nanocarreadores were obtained and the chemopreventive activity and the antiangiogenic effect of these systems represent a promising alternative for the treatment of cutaneous neoplasias. |
publishDate |
2018 |
dc.date.accessioned.fl_str_mv |
2018-06-27T11:09:43Z |
dc.date.issued.fl_str_mv |
2018-04-11 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
DIAS, Marina França. Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele. 2018. 102 f. Tese (Doutorado em Nanotecnologia Farmacêutica em Rede) - Universidade Federal de Goiás, Goiânia, 2018. |
dc.identifier.uri.fl_str_mv |
http://repositorio.bc.ufg.br/tede/handle/tede/8601 |
dc.identifier.dark.fl_str_mv |
ark:/38995/001300000b9wz |
identifier_str_mv |
DIAS, Marina França. Desenvolvimento e avaliação da atividade quimiopreventiva de nanopartículas contendo imiquimode em modelo murino de câncer de pele. 2018. 102 f. Tese (Doutorado em Nanotecnologia Farmacêutica em Rede) - Universidade Federal de Goiás, Goiânia, 2018. ark:/38995/001300000b9wz |
url |
http://repositorio.bc.ufg.br/tede/handle/tede/8601 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.program.fl_str_mv |
-8945451959856925315 |
dc.relation.confidence.fl_str_mv |
600 600 600 600 |
dc.relation.department.fl_str_mv |
6010281161524209375 |
dc.relation.cnpq.fl_str_mv |
-1498234366838932019 |
dc.relation.sponsorship.fl_str_mv |
-2555911436985713659 |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.publisher.program.fl_str_mv |
Programa de Pós-graduação em Nanotecnologia Farmacêutica em Rede (FF) |
dc.publisher.initials.fl_str_mv |
UFG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Faculdade Farmácia - FF (RG) |
publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFG instname:Universidade Federal de Goiás (UFG) instacron:UFG |
instname_str |
Universidade Federal de Goiás (UFG) |
instacron_str |
UFG |
institution |
UFG |
reponame_str |
Repositório Institucional da UFG |
collection |
Repositório Institucional da UFG |
bitstream.url.fl_str_mv |
http://repositorio.bc.ufg.br/tede/bitstreams/a7689134-9d4d-48ec-a690-408a8f609778/download http://repositorio.bc.ufg.br/tede/bitstreams/58ab8ea3-50bc-4bf5-b127-ccc4bf82af06/download http://repositorio.bc.ufg.br/tede/bitstreams/5f262478-1342-4498-a54f-5758b5ff9bf7/download http://repositorio.bc.ufg.br/tede/bitstreams/934ac161-3de4-4371-99d2-7f8933672dd0/download http://repositorio.bc.ufg.br/tede/bitstreams/9b73a680-d874-412b-b3d2-5d1615870762/download |
bitstream.checksum.fl_str_mv |
bd3efa91386c1718a7f26a329fdcb468 4afdbb8c545fd630ea7db775da747b2f d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e 86e73a57e2ce0a02cb1666dfe5988ce3 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFG - Universidade Federal de Goiás (UFG) |
repository.mail.fl_str_mv |
tasesdissertacoes.bc@ufg.br |
_version_ |
1813816954634371072 |